Back to results
US 9,750,808 B2Granted
Formulation of human antibodies for treating TNF-alpha associated disorders
AssigneeAbbVie Biotechnology Ltd.
InventorsHans-Juergen Krause, Lisa Baust, Michael Dickes
Life of this patent
Estimating the term…
Abstract
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
Claims30
A stable liquid aqueous pharmaceutical formulation comprising:
- a human anti-human Tumor Necrosis Factor alpha (TNFα) IgG1 antibody at a concentration of 45 to 105 mg/ml, wherein the antibody is D2E7, and a buffer system;
- wherein the formulation is isotonic, suitable for single-use subcutaneous injection, and has a pH of 4 to 8.
Dependencies are inferred from the claim text.